Patients' perspective on pulmonary rehabilitation: experiences of European and American individuals with chronic respiratory diseases by Rochester, Carolyn et al.
This is a repository copy of Patients' perspective on pulmonary rehabilitation: experiences 
of European and American individuals with chronic respiratory diseases.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/157008/
Version: Published Version
Article:
Rochester, Carolyn, Vogiatzis, Ioannis, Powell, Pippa et al. (2 more authors) (2018) 
Patients' perspective on pulmonary rehabilitation: experiences of European and American 
individuals with chronic respiratory diseases. ERJ open research. pp. 1-4. ISSN 
2312-0541 
https://doi.org/10.1183/23120541.00085-2018
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Patients’ perspective on pulmonary
rehabilitation: experiences of European
and American individuals with chronic
respiratory diseases
To the Editor:
Despite the fact that pulmonary rehabilitation (PR) is the most powerful nonpharmacological intervention to
improve the symptoms, exercise capacity and quality of life of people living with chronic lung disease [1],
fewer than 2% of eligible patients enrol [2, 3]. While preparing a joint American Thoracic Society (ATS)/
European Respiratory Society (ERS) Policy Statement on pulmonary rehabilitation [4], we developed a
survey to better understand patients’ perspectives on PR, and to identify challenges faced both by patients
who have taken part in PR and those who might be eligible but have not had the opportunity. The survey
was disseminated via the European Lung Foundation/ERS and ATS Public Advisory Roundtable professional
patient networks, and via the COPD Foundation and Pulmonary Fibrosis Foundation to patients with a
wide range of chronic lung diseases. The survey was available online from July, 2014 to November, 2014 in
10 languages (Dutch, English, Flemish, French, German, Greek, Italian, Polish, Portuguese and Spanish).
Responses were received from 1685 people (73% female) with self-reported chronic lung disease in 29
countries (USA: 71.1%; Europe: 27.4%; others: 1.5%) and were included in the analyses (table 1).
A majority of patients were 61 years of age or older (54.7%). 92% of respondents thought that PR should
be a part of healthcare services available to all patients that might benefit, yet 46% of respondents had
never taken part in a PR programme. 60% reported having experienced challenges to taking part in PR
(table 1). Approximately two-fifths of respondents reported that their healthcare provider had never told
them about PR, or the benefits of PR for people living with chronic lung disease. 18% felt they did not
have enough information to decide about participating or were not sure it would help them. Nearly
one-fifth of respondents faced logistical challenges, such as no PR service available or lack of insurance
coverage. Emotional challenges were also an obstacle to participation.
Of the respondents who had participated in PR, most had heard about it through their healthcare provider
(table 1). A majority of these individuals reported improvements in physical functioning in daily life,
mood or sense of emotional wellbeing, knowledge about their lung condition, control of symptoms, social
functioning, or a combination thereof (table 1). PR participants were asked to respond to the question
“What would you say to someone considering attending a PR session for the first time?”. Representative
responses included: “Absolutely do it!”, “A must!”, “It allows you to move around and breathe better”,
“Absolutely go all in!”, “Be open about your symptoms and condition”, “Begin as soon as possible”, “Best
thing I ever did to help manage this disease”, “Don’t be a damn fool – go and help yourself”, “Don’t be
scared”, “It will change your life”, and “It works!”. None of the respondents made negative comments or
recommended against participation in PR. Patients who had participated also offered suggestions as to
how to improve the PR experience. Representative suggestions included having PR facilities closer to
home, having appropriate funding and lower “out of pocket” costs, a longer duration of PR programme or
the opportunity to do two PR programmes per year, opportunity to transition to a maintenance
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TABLE 1 Patient survey on experiences relating to pulmonary rehabilitation (PR)
Total number of respondents n 1685
What is your age group?
18–30 years 24 (1.4)
31–50 years 287 (17.0)
51–60 years 452 (26.8)
61–70 years 520 (31.4)
>70 years 393 (23.3)
Not reported 9 (0.1)
Gender
Women 1229 (72.9)
Men 450 (26.7)
Not reported 6 (0.4)
Have you ever been told about PR by your healthcare provider?
Yes 1009 (59.9)
No 614 (36.4)
Not sure 62 (3.7)
Has a healthcare provider ever discussed the benefits of PR with you?
Yes 939 (55.7)
No 702 (41.7)
Not sure 41 (2.4)
Not reported 3 (0.2)
Have you ever taken part in PR?
Yes 904 (53.6)
No 770 (45.7)
Not sure 10 (0.6)
Not reported 1 (0.1)
If you have taken part in PR, how did you hear about it? You can choose more than one option.
Healthcare provider 807 (89.3)
On the internet 74 (8.2)
Published literature, such as newspapers or academic journals 46 (5.1)
Pamphlet/flyer 30 (3.3)
Advertisement (on TV, radio or in a magazine) 5 (0.6)
A friend or a family member 69 (7.6)
Someone who had taken part in PR 109 (12.1)
If you have taken part in PR, did you….?
Complete the whole programme 777 (86.0)
Stop early 98 (10.8)
Not reported 29 (3.2)
Reasons for stopping early (if applicable) (individual patient responses below):
Medical comorbidities/accident
Costs of the PR programme
Exacerbation of chronic lung disease
Death in the family
Still actively participating in the PR programme
If you have participated in PR, what is the lung condition for which you were referred?
COPD 495 (54.8)
Pulmonary fibrosis (or interstitial lung disease) 201 (22.2)
Pulmonary hypertension 56 (6.2)
Asthma 41 (4.5)
Cystic fibrosis 12 (1.3)
Bronchiectasis 15 (1.7)
Lung cancer 14 (1.6)
Other (including but not limited to) (individual patient responses below): 70 (7.7)
After pneumonia
α1-antitrypsin deficiency
Chronic bronchitis
After lung transplantation
Do you think that PR should be a part of healthcare services available to all patients that might benefit from it?
Yes 1549 (91.9)
No 3 (0.2)
Not sure 111 (6.6)
Not reported 22 (1.3)
Continued
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programme, having the option for PR sessions during evenings or the weekend days, addition of yoga and/
or meditation to the PR programme, and the importance of individualisation of the PR programme to
each patient’s condition (including the educational component and need for staff to have knowledge of
respiratory disorders other than chronic obstructive pulmonary disease (COPD)). Notably, three-fifths of
respondents reported that they experienced one or more challenges to taking part in PR.
In 2015, the official ATS/ERS policy statement on enhancing implementation, use and delivery of
pulmonary rehabilitation highlighted the need to increase patients’ and healthcare providers’ awareness
and knowledge of PR, as well as to increase patients’ access to PR [4]. For example, it was recommended
that professional societies and patient advocacy and education experts develop education materials for
people living with chronic respiratory disease regarding the process and benefits of PR. Public awareness
campaigns are also needed. The current survey data confirms the need for greater healthcare professionals’
knowledge and awareness of PR to foster patient referrals, and for new PR services to reduce travel
TABLE 1 Continued
Have you experienced any challenges to taking part in PR? (Multiple answers possible.)
No challenges 670 (39.8)
Never heard of PR 377 (22.4)
Not enough information to decide whether I want to participate 162 (9.6)
Not sure whether it would help me 150 (8.9)
Worried it might be painful 37 (2.2)
There is no PR service in my area 134 (8.0)
The doctor did not think it would help me 44 (2.6)
Did not qualify for the service in my area 38 (2.3)
Cannot get to the appointments, because the service is too far away 52 (3.1)
Not covered by my insurance 93 (5.5)
Lack of encouragement from the people running the program/staff 45 (2.7)
Family not supportive 19 (1.1)
Low self-confidence or anxiety 72 (4.3)
Other (including, but not limited to) (individual patient responses below): 247 (14.7)
Medical comorbidities
Disease instability/frequent exacerbations
Inconvenient PR times (still working/need for childcare)
PR programme (initially) limited to COPD patients only
Poor/no PR facilities available
Exercising with people on oxygen supplements was detrimental
No/pending approval from insurance
Lack of clarity in the referral process and reimbursement
(Co-)pay is too expensive
Transportation problems
Patient believes to be too ill to participate in PR
Patients believes to be active enough/PR not necessary
Physician unknown with the effects of PR
If you have participated in PR, what do you feel were the major benefits of the programme for you? You can choose more
than one option.
Improved physical functioning in daily life 658 (75.8)
Improved mood or sense of emotional wellbeing 439 (48.6)
Improved knowledge about lung condition 474 (52.4)
Improved control of symptoms 416 (46.0)
Improved social functioning 261 (28.9)
Other (including but not limited to) (individual patient responses below): 277 (30.6)
A combination of the abovementioned improvements
Improved quality of life
Improved mobility
Empowering
Improved lifestyle
Improved self-confidence
Improved understanding of my problems
No change/improvement
Data are presented as n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease.
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distance and transportation problems, for increased insurance coverage for PR, and expanded PR services
that do not focus solely on COPD.
Our survey-based study has some limitations. Given that the majority of respondents were from Europe
and North America, the generalisability of our findings to other first world and/or developing countries is
unknown. Moreover, the participation and engagement of many of our respondents in patient networks
and health societies might have introduced bias into the survey findings, since these individuals may have
been especially motivated to take control of and manage their respiratory disease. Future efforts to learn
more about the perspectives of individuals from other countries underrepresented in the present survey,
and those not engaged in patient networks or health societies would be both informative and beneficial.
In keeping with the ATS/ERS policy statement on PR [4], however, this survey demonstrates clearly that
people with chronic lung diseases in Europe and the USA want to learn about and be able to participate in
PR, yet are often unaware of it, its benefits or lack access to it. Importantly, these findings are probably
“the tip of the iceberg”, since only people with computer and internet access could respond to this survey.
Referrals, access to and uptake of PR are likely significantly further diminished among those from more
remote, under-served or poverty-stricken areas [5]. We believe this is an important healthcare disparity
that should be addressed by healthcare providers and health systems in the years to come.
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